Stephens Consulting’s Nurix Therapeutics NRIX Stock Holding History

Stephens Consulting’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$357	–	1712
2025 Q1	$357	Buy	+30	New	+$502	﹤0.01%	1286

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's NRIX Position: Q2 2025 in Review

Stephens Consulting sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 30 shares — an estimated $357 sold.

Stephens Consulting first reported a position in NRIX in Q1 2025 and held it in 1 quarter. The position peaked at $357 in Q1 2025. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

Stephens Consulting reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 30 Nurix Therapeutics shares in Q2 2025, an estimated $357.
Stephens Consulting first reported a position in Nurix Therapeutics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Nurix Therapeutics position peaked at $357 in Q1 2025.
163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.